Winer, I., Gilbert, L., Vaishampayan, U., Rosen, S., Hoimes, C., Muzaffar, J., … Strauss, J. (2020). 347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial. In Regular and young investigator award abstracts (p. A211.2-A212). BMJ Publishing Group Ltd. https://doi.org/10.1136/jitc-2020-sitc2020.0347

Winer, Ira, Lucy Gilbert, Ulka Vaishampayan, Seth Rosen, Christopher Hoimes, Jameel Muzaffar, Anna Spreafico, et al. “347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial.” In Regular and Young Investigator Award Abstracts, A211.2-A212. BMJ Publishing Group Ltd, 2020. https://doi.org/10.1136/jitc-2020-sitc2020.0347.

Winer I, Gilbert L, Vaishampayan U, Rosen S, Hoimes C, Muzaffar J, et al. 347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial. In: Regular and young investigator award abstracts. BMJ Publishing Group Ltd; 2020. p. A211.2-A212.

Winer, Ira, et al. “347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial.” Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, 2020, p. A211.2-A212. Crossref, doi:10.1136/jitc-2020-sitc2020.0347.

Winer I, Gilbert L, Vaishampayan U, Rosen S, Hoimes C, Muzaffar J, Spreafico A, McDermott D, Chu Q, Dumas O, Chauhan A, Chaudhry A, Tomczak P, Boni V, Bruno D, Curtis K, Wang Y, Dorn E, Rege J, Du Y, Bidollari I, Sun L, Putiri E, Losey H, Dezube B, Ernstoff M, Velcheti V, Strauss J. 347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial. Regular and young investigator award abstracts. BMJ Publishing Group Ltd; 2020. p. A211.2-A212.